SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (452)4/13/2003 10:26:45 AM
From: nigel bates  Read Replies (1) of 469
 
According to the Sundays, Celltech have nearly 50% secured.
They will retain bioinformatics division and the small molecule drug discovery unit; sell Zavesca (est. £20m), and the proteomics business (est. £10m).

Per Fellner, "The net cash from the deal will be in the low millions, after all the costs, but we will get back more from the assets we sell..."
No kidding.

Sir Chris claims the 'gigantic lease liabilities' put him off bidding.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News